Evidence map›Paper›PMID 24729973›Full record

ArticleBioMed research international2014

A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.

Zhiyuan Wu, Yunqing Zhang, Xinju Zhang, Xiao Xu, Zhihua Kang, Shibao Li, Chen Zhang, Bing Su, Ming Guan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Zhiyuan WuCentral Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China ; Department of Laboratory Medicine, Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-0466-5996
Yunqing ZhangDepartment of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xinju ZhangCentral Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Xiao XuCentral Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Zhihua KangDepartment of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Shibao LiDepartment of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Chen ZhangDepartment of Laboratory Medicine, Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai, China.
Bing SuDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA.
Ming GuanCentral Laboratory, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China ; Department of Laboratory Medicine, Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai, China ; Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-8796-2653
Fudan University · CNRoswell Park Comprehensive Cancer Center · USSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multiplex snapback primer system was developed for the simultaneous detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia chromosome- (Ph-) negative myeloproliferative neoplasms (MPNs). The multiplex system comprises two snapback versus limiting primer sets for JAK2 and MPL mutation enrichment and detection, respectively. Linear-After exponential (LATE) PCR strategy was employed for the primer design to maximize the amplification efficiency of the system. Low ionic strength buffer and rapid PCR protocol allowed for selective amplification of the mutant alleles. Amplification products were analyzed by melting curve analysis for mutation identification. The multiplex system archived 0.1% mutation load sensitivity and <5% coefficient of variation inter-/intra-assay reproducibility. 120 clinical samples were tested by the multiplex snapback primer assay, and verified with amplification refractory system (ARMS), quantitative PCR (qPCR) and Sanger sequencing method. The multiplex system, with a favored versatility, provided the molecular diagnosis of Ph-negative MPNs with a suitable implement and simplified the genetic test process.

Indexed as

Base SequenceDNA Mutational AnalysisDNA PrimersGenetic MarkersGenetic TestingHumansJanus Kinase 2Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMolecular Sequence DataMultiplex Polymerase Chain ReactionMutationPolymorphism, Single NucleotideReceptors, ThrombopoietinDNA PrimersGenetic MarkersJAK2 protein, humanJanus Kinase 2MPL protein, humanReceptors, Thrombopoietin

Identifiers

PMID24729973
PMCPMC3960525
OpenAlexW2022982566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.